this post was submitted on 23 Jan 2024
457 points (86.9% liked)
Microblog Memes
11434 readers
196 users here now
A place to share screenshots of Microblog posts, whether from Mastodon, tumblr, ~~Twitter~~ X, KBin, Threads or elsewhere.
Created as an evolution of White People Twitter and other tweet-capture subreddits.
RULES:
- Your post must be a screen capture of a microblog-type post that includes the UI of the site it came from, preferably also including the avatar and username of the original poster. Including relevant comments made to the original post is encouraged.
- Your post, included comments, or your title/comment should include some kind of commentary or remark on the subject of the screen capture. Your title must include at least one word relevant to your post.
- You are encouraged to provide a link back to the source of your screen capture in the body of your post.
- Current politics and news are allowed, but discouraged. There MUST be some kind of human commentary/reaction included (either by the original poster or you). Just news articles or headlines will be deleted.
- Doctored posts/images and AI are allowed, but discouraged. You MUST indicate this in your post (even if you didn't originally know). If an image is found to be fabricated or edited in any way and it is not properly labeled, it will be deleted.
- Absolutely no NSFL content.
- Be nice. Don't take anything personally. Take political debates to the appropriate communities. Take personal disagreements & arguments to private messages.
- No advertising, brand promotion, or guerrilla marketing.
RELATED COMMUNITIES:
founded 2 years ago
MODERATORS
We're talking about glioblastoma here, there's not much "continous" treatment to be had and temozolomide's and bevacizumab's patents have run out (edit: also bevacizumab doesn't prolong overall survival at all and temozolomide is ineffective in MGMT-positive patients, i.e. about half).
That said, I'm not sure why the other commenter is so dismissive of your idea. There's plenty of drugs that have been kept in the cupboard (e.g. desloratadine) or not seeking approval for certain illnesses so a "new", more expensive drug could be sold (e.g. no rituximab trials for multiple sclerosis so Roche could sell Ocrelizumab, no Bevacizumab trials for macular degeneration so they could sell Ranibizumab) – and certainly many more that we never heard about.